doi: 10.1161/CIRCULATIONAHA.105.580506
(Circulation. 2006;113:671-678.)
© 2006 American Heart Association, Inc.
Heart Failure |
Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure
From the University Medical Center Groningen, University of Groningen, the Netherlands (H.L.H., D.J.V.V.); Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, UK (D.N., S.P.); The Cardiovascular Division, Brigham and Women’s Hospital, Boston, Mass (M.A.P.); Sahlgrenska University Hospital/Östra Göteborg, Sweden (K.S.); University of Glasgow, Glasgow, UK (J.J.V.M.); Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada (S.Y.); Duke University Medical Center, Durham, NC (C.B.G.); AstraZeneca LP, Wilmington, Del (E.L.M.); Karolinska Hospital, Stockholm, Sweden (J.Ö.); Medisch Centrum Alkmaar, the Netherlands (J.H.C.); and the Department of Clinical Pharmacology, University of Groningen, the Netherlands (D.d.Z.).
Correspondence to Dr Hans L. Hillege, Department of Cardiology, Thoraxcenter, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands. E-mail h.hillege{at}tcc.umcg.nl
Received August 31, 2005; revision received November 4, 2005; accepted November 23, 2005.
Background— Decreased renal function has been found to be an independent risk factor for cardiovascular outcomes in patients with chronic heart failure (CHF) with markedly reduced left ventricular ejection fraction (LVEF). The aim of this analysis was to evaluate the prognostic importance of renal function in a broader spectrum of patients with CHF.
Methods and Results— The Candesartan in Heart Failure:Assessment of Reduction in Mortality and Morbidity (CHARM) program consisted of three component trials that enrolled patients with symptomatic CHF, based on use of ACE inhibitors and reduced (
40%) or preserved LVEF (>40%). Entry baseline creatinine was required to be below 3.0 mg/dL (265 µmol/L). Routine baseline serum creatinine assessments were done in 2680 North American patients. An analysis of the estimated glomerular filtration rate (eGFR), using the Modification of Diet in Renal Disease equation and LVEF on risk of cardiovascular death or hospitalization for heart failure, as well as on all-cause mortality, was conducted on these 2680 patients. The proportion of patients with eGFR <60 mL/min per 1.73 m2 was 36.0%; 42.6% for CHARM-Alternative, 33.0% for CHARM-Added, and 34.7% for CHARM-Preserved. During the median follow-up of 34.4 months (total 6493 person-years), the primary outcome of cardiovascular death or hospital admission for worsening CHF occurred in 950 of 2680 subjects. Both reduced eGFR and lower LVEF were found to be significant independent predictors of worse outcome after adjustment for major confounding baseline clinical characteristics. The risk for cardiovascular death or hospitalization for worsening CHF as well as the risk for all-cause mortality increased significantly below an eGFR of 60 mL/min per 1.73 m2 (adjusted hazard ratio, 1.54 for 45 to 60 mL/min per 1.73 m2 and 1.86 for <45 mL/min per 1.73 m2 for the primary outcome, both P<0.001, and hazard ratio of 1.50, P=0.006, and 1.91, P=0.001, respectively, for all-cause mortality). The prognostic value of eGFR was not significantly different among the three component trials. There was no significant interaction between renal function, the effect of candesartan, and clinical outcome.
Conclusions— Impaired renal function is independently associated with heightened risk for death, cardiovascular death, and hospitalization for heart failure in patients with CHF with both preserved as well as reduced LVEF. There was no evidence that the beneficial effect of candesartan was modified by baseline eGFR.
Key Words: heart failure • angiotensin • kidney • risk factors • prognosis
This article has been cited by other articles:
 |
|
 |
|
  G. C.M. Linssen, K. Damman, H. L. Hillege, G. Navis, D. J. van Veldhuisen, and A. A. Voors Urinary N-Terminal Prohormone Brain Natriuretic Peptide Excretion in Patients With Chronic Heart Failure Circulation, July 7, 2009; 120(1): 35 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Kazory and E A Ross Ultrafiltration for decompensated heart failure: renal implications Heart, July 1, 2009; 95(13): 1047 - 1051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. F. Lewis, S. D. Solomon, K. A. Jablonski, M. M. Rice, F. Clemenza, J. Hsia, A. P. Maggioni, M. Zabalgoitia, T. Huynh, T. E. Cuddy, et al. Predictors of Heart Failure in Patients With Stable Coronary Artery Disease: A PEACE Study Circ Heart Fail, May 1, 2009; 2(3): 209 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Sandner, D. Zimpfer, P. Zrunek, A. Rajek, H. Schima, D. Dunkler, M. Grimm, E. Wolner, and G. M. Wieselthaler Renal Function and Outcome After Continuous Flow Left Ventricular Assist Device Implantation Ann. Thorac. Surg., April 1, 2009; 87(4): 1072 - 1078. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Pizzarelli, F. Lauretani, S. Bandinelli, G. B. Windham, A. M. Corsi, S. V. Giannelli, L. Ferrucci, and J. M. Guralnik Predictivity of survival according to different equations for estimating renal function in community-dwelling elderly subjects Nephrol. Dial. Transplant., April 1, 2009; 24(4): 1197 - 1205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Swedberg Tailoring therapy in chronic heart failure Eur J Heart Fail Suppl, April 1, 2009; 8(suppl_1): i25 - i29. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wedel, J. J.V. McMurray, M. Lindberg, J. Wikstrand, J. G.F. Cleland, J. H. Cornel, P. Dunselman, A. Hjalmarson, J. Kjekshus, M. Komajda, et al. Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide Eur J Heart Fail, March 1, 2009; 11(3): 281 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Damman, V. M. van Deursen, G. Navis, A. A. Voors, D. J. van Veldhuisen, and H. L. Hillege Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J. Am. Coll. Cardiol., February 17, 2009; 53(7): 582 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ronco, M. Haapio, A. A. House, N. Anavekar, and R. Bellomo Cardiorenal Syndrome J. Am. Coll. Cardiol., November 4, 2008; 52(19): 1527 - 1539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. K. M. Windt, R. H. Henning, A. C. A. Kluppel, Y. Xu, D. de Zeeuw, and R. P. E. van Dokkum Myocardial infarction does not further impair renal damage in 5/6 nephrectomized rats Nephrol. Dial. Transplant., October 1, 2008; 23(10): 3103 - 3110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Damman, D. J. van Veldhuisen, G. Navis, A. A. Voors, and H. L. Hillege Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure Eur J Heart Fail, October 1, 2008; 10(10): 997 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. C. Gerstein, K. Swedberg, J. Carlsson, J. J. V. McMurray, E. L. Michelson, B. Olofsson, M. A. Pfeffer, S. Yusuf, and for the CHARM Program Investigators The Hemoglobin A1c Level as a Progressive Risk Factor for Cardiovascular Death, Hospitalization for Heart Failure, or Death in Patients With Chronic Heart Failure: An Analysis of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program Arch Intern Med, August 11, 2008; 168(15): 1699 - 1704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Graf, T. Hucko, and P. Stawowy Cardiac Benefits of Mineralocorticoid Receptor Inhibition in Renal Failure Hypertension, August 1, 2008; 52(2): 209 - 210. [Full Text] [PDF]
|
|
|
|
|
|
S. Neuhold, M. Huelsmann, G. Strunk, B. Stoiser, J. Struck, N. G. Morgenthaler, A. Bergmann, D. Moertl, R. Berger, and R. Pacher Comparison of Copeptin, B-Type Natriuretic Peptide, and Amino-Terminal Pro-B-Type Natriuretic Peptide in Patients With Chronic Heart Failure: Prediction of Death at Different Stages of the Disease J. Am. Coll. Cardiol., July 22, 2008; 52(4): 266 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Schou, C. Torp-Pedersen, F. Gustafsson, J. Abdulla, and L. Kober Wall motion index, estimated glomerular filtration rate and mortality risk in patients with heart failure or myocardial infarction: A pooled analysis of 18,010 patients Eur J Heart Fail, July 1, 2008; 10(7): 682 - 688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Shah, T. Thenappan, S. Rich, L. Tian, S. L. Archer, and M. Gomberg-Maitland Association of Serum Creatinine With Abnormal Hemodynamics and Mortality in Pulmonary Arterial Hypertension Circulation, May 13, 2008; 117(19): 2475 - 2483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Klein, B. M. Massie, J. D. Leimberger, C. M. O'Connor, I. L. Pina, K. F. Adams Jr, R. M. Califf, M. Gheorghiade, and for the OPTIME-CHF Investigators Admission or Changes in Renal Function During Hospitalization for Worsening Heart Failure Predict Postdischarge Survival: Results From the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Circ Heart Fail, May 1, 2008; 1(1): 25 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Amsalem, M. Garty, R. Schwartz, A. Sandach, S. Behar, A. Caspi, S. Gottlieb, D. Ezra, B. S. Lewis, and J. Leor Prevalence and significance of unrecognized renal insufficiency in patients with heart failure Eur. Heart J., April 2, 2008; 29(8): 1029 - 1036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Nohria, V. Hasselblad, A. Stebbins, D. F. Pauly, G. C. Fonarow, M. Shah, C. W. Yancy, R. M. Califf, L. W. Stevenson, and J. A. Hill Cardiorenal Interactions: Insights From the ESCAPE Trial J. Am. Coll. Cardiol., April 1, 2008; 51(13): 1268 - 1274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Weinrauch, J. Lin, and S. D. Solomon Mapping Directions for the Cardiorenal Conundrum: Where You End Up Depends Upon Where You Started, So Where Do We Go From Here? J. Am. Coll. Cardiol., April 1, 2008; 51(13): 1275 - 1276. [Full Text] [PDF]
|
|
|
|
|
|
E. F. Lewis, E. J. Velazquez, S. D. Solomon, A. S. Hellkamp, J. J.V. McMurray, J. Mathias, J.-L. Rouleau, A. P. Maggioni, K. Swedberg, L. Kober, et al. Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study Eur. Heart J., March 2, 2008; 29(6): 748 - 756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. G. Athyros, A. I. Kakafika, K. Tziomalos, A. Karagiannis, and D. P. Mikhailidis CORONA, Statins, and Heart Failure: Who Lost the Crown? Angiology, March 1, 2008; 59(1): 5 - 8. [PDF]
|
|
|
|
|
|
R. Pfister, H. Diedrichs, A. Schiedermair, S. Rosenkranz, M. Hellmich, E. Erdmann, and C. A. Schneider Prognostic impact of NT-proBNP and renal function in comparison to contemporary multi-marker risk scores in heart failure patients Eur J Heart Fail, March 1, 2008; 10(3): 315 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Gardner, K. S. Chong, E. O'Meara, A. Jardine, I. Ford, and T. A. McDonagh Renal dysfunction, as measured by the modification of diet in renal disease equations, and outcome in patients with advanced heart failure Eur. Heart J., December 2, 2007; 28(24): 3027 - 3033. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W.L. Hartog, A. A. Voors, C. G. Schalkwijk, J. Scheijen, T. D.J. Smilde, K. Damman, S. J.L. Bakker, A. J. Smit, and D. J. van Veldhuisen Clinical and prognostic value of advanced glycation end-products in chronic heart failure Eur. Heart J., December 1, 2007; 28(23): 2879 - 2885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Desai, K. Swedberg, J. J.V. McMurray, C. B. Granger, S. Yusuf, J. B. Young, M. E. Dunlap, S. D. Solomon, J. W. Hainer, B. Olofsson, et al. Incidence and Predictors of Hyperkalemia in Patients With Heart Failure: An Analysis of the CHARM Program J. Am. Coll. Cardiol., November 13, 2007; 50(20): 1959 - 1966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Witteles, D. Kao, D. Christopherson, K. Matsuda, R. H. Vagelos, D. Schreiber, and M. B. Fowler Impact of Nesiritide on Renal Function in Patients With Acute Decompensated Heart Failure and Pre-Existing Renal Dysfunction: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1835 - 1840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Verma, N. S. Anavekar, A. Meris, J. J. Thune, J. M. O. Arnold, J. K. Ghali, E. J. Velazquez, J. J.V. McMurray, M. A. Pfeffer, and S. D. Solomon The Relationship Between Renal Function and Cardiac Structure, Function, and Prognosis After Myocardial Infarction: The VALIANT Echo Study J. Am. Coll. Cardiol., September 25, 2007; 50(13): 1238 - 1245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Damman, G. Navis, T. D.J. Smilde, A. A. Voors, W. van der Bij, D. J. van Veldhuisen, and H. L. Hillege Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction Eur J Heart Fail, September 1, 2007; 9(9): 872 - 878. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Costello-Boerrigter, G. Boerrigter, G. J. Harty, A. Cataliotti, M. M. Redfield, and J. C. Burnett Jr Mineralocorticoid Escape by the Kidney But Not the Heart in Experimental Asymptomatic Left Ventricular Dysfunction Hypertension, September 1, 2007; 50(3): 481 - 488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bruch, C. Bruch, J. Sindermann, G. Breithardt, and R. Gradaus Prevalence and prognostic impact of comorbidities in heart failure patients with implantable cardioverter defibrillator Europace, August 1, 2007; 9(8): 681 - 686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. O'Meara, T. Clayton, M. B. McEntegart, J. J.V. McMurray, I. L. Pina, C. B. Granger, J. Ostergren, E. L. Michelson, S. D. Solomon, S. Pocock, et al. Sex Differences in Clinical Characteristics and Prognosis in a Broad Spectrum of Patients With Heart Failure: Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Program Circulation, June 19, 2007; 115(24): 3111 - 3120. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Kielstein, S. R. Salpeter, S. M. Bode-Boeger, J. P. Cooke, and D. Fliser Symmetric dimethylarginine (SDMA) as endogenous marker of renal function--a meta-analysis Nephrol. Dial. Transplant., September 1, 2006; 21(9): 2446 - 2451. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Sarafidis and G. L. Bakris Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease Nephrol. Dial. Transplant., September 1, 2006; 21(9): 2366 - 2374. [Full Text] [PDF]
|
|
|
|
|
|
J. T. Kielstein, J. P. Cooke, and C. Zoccali Letter by Kielstein et al Regarding Article, "Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure" Circulation, August 8, 2006; 114(6): e242 - e242. [Full Text] [PDF]
|
|
|
|
|
|
H. L. Hillege and D. J. van Veldhuisen Response to Letter Regarding Article, "Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure" Circulation, August 8, 2006; 114(6): e243 - e243. [Full Text] [PDF]
|
|